AZD-5305

Generic Name: AZD-5305

Clinical Trials

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Phase 3

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: Saruparib
Drug: Placebo
Drug: Androgen Deprivation Therapy (ADT)
Drug: Abiraterone + Prednisolone/Prednisone

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 700

Registration Number: NCT06952803

Locations: 🇹🇭
Research Site, Khon Kaen, Thailand

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

Phase 1

Recruiting

Conditions: Advanced Solid Malignancies

Interventions: Drug: Saruparib
Drug: Digoxin
Drug: Rabeprazole
Drug: Furosemide
Drug: Metformin Hydrochloride
Drug: Rosuvastatin

First Posted Date: 2025-03-27

Last Posted Date: 2025-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 45

Registration Number: NCT06899061

Locations: 🇷🇴
Research Site, Cluj Napoca, Romania

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2

Not yet recruiting

Conditions: Lung Small Cell Carcinoma, I Subtype
Lung Small Cell Carcinoma, N Subtype
Lung Small Cell Carcinoma, P Subtype
Extensive Stage Lung Small Cell Carcinoma
Lung Small Cell Carcinoma, A Subtype

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ceralasertib
Biological: Durvalumab
Drug: Etoposide
Procedure: Magnetic Resonance Imaging
Drug: Platinum Compound
Biological: Monalizumab
Procedure: Positron Emission Tomography
Radiation: Thoracic Radiation Therapy
Drug: Saruparib

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-28

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 900

Registration Number: NCT06769126

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Phase 3

Recruiting

Conditions: Metastatic Castration-Sensitive Prostate Cancer

Interventions: Drug: Placebo
Drug: Saruparib
Drug: Abiraterone Acetate
Drug: Darolutamide
Drug: Enzalutamide

First Posted Date: 2023-11-07

Last Posted Date: 2025-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 1800

Registration Number: NCT06120491

Locations: 🇬🇧
Research Site, Truro, United Kingdom

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Advanced Solid Malignancies

Interventions: Drug: AZD5305
Drug: Itraconazole

First Posted Date: 2022-10-10

Last Posted Date: 2024-06-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT05573724

Locations: 🇷🇴
Research Site, Cluj-Napoca, Romania

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

Phase 1

Recruiting

Conditions: Metastatic Prostate Cancer

Interventions: Drug: AZD5305
Drug: Apalutamide
Drug: Enzalutamide
Drug: Abiraterone Acetate
Drug: Darolutamide

First Posted Date: 2022-05-10

Last Posted Date: 2025-05-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 190

Registration Number: NCT05367440

Locations: 🇬🇧
Research Site, Plymouth, United Kingdom

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Phase 1

Recruiting

Conditions: Ovarian Cancer
Colorectal Cancer
Endometrial Cancer
Small Cell Lung Cancer Only in Module 5
Breast Cancer
Pancreatic Cancer
Prostate Cancer
Additional Indications Below for Module 4 and 5
Non-small Cell Lung Cancer
Bladder Cancer

Interventions: Drug: AZD5305
Drug: Paclitaxel
Drug: T- Dxd
Drug: Dato-DXd
Drug: Camizestrant
Drug: Carboplatin

First Posted Date: 2020-11-25

Last Posted Date: 2025-04-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 804

Registration Number: NCT04644068

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Phase 1

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Radiation: Radiotherapy
Drug: Olaparib Oral Tablet [Lynparza]
Drug: AZD1390
Drug: Ceralasertib
Drug: AZD5305
Drug: Durvalumab

First Posted Date: 2020-09-16

Last Posted Date: 2025-04-01

Lead Sponsor: University of Leeds

Target Recruit Count: 200

Registration Number: NCT04550104

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧
Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom

and more 8 locations

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Early Phase 1

Recruiting

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma
Stage II Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Metastatic Pancreatic Ductal Adenocarcinoma
Stage III Pancreatic Cancer AJCC v8
Unresectable Pancreatic Ductal Adenocarcinoma
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Olaparib
Drug: Cobimetinib
Drug: Onvansertib
Drug: Azenosertib
Biological: Tremelimumab
Drug: Saruparib

First Posted Date: 2019-07-02

Last Posted Date: 2025-02-13

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 90

Registration Number: NCT04005690

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy